Apoptosis
Apoptosis(凋亡)
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
- Caspase(102)
- 14.3.3 Proteins(2)
- Apoptosis Inducers(45)
- Bax(7)
- Bcl-2 Family(122)
- Bcl-xL(8)
- c-RET(9)
- IAP(27)
- KEAP1-Nrf2(67)
- MDM2(15)
- p53(128)
- PC-PLC(5)
- PKD(8)
- RasGAP (Ras- P21)(1)
- Survivin(8)
- Thymidylate Synthase(10)
- TNF-α(151)
- Other Apoptosis(900)
- Apoptosis Detection
- Caspase Substrate
- APC(6)
- PD-1/PD-L1 interaction(91)
- ASK1(3)
- PAR4(2)
- RIP kinase(52)
- FKBP(20)
- Pyroptosis(32)
Apoptosis 相关产品(2721)
- GC10354Daunorubicin HClCAS: 23541-50-6纯度: >99.00% / >98.00%
Daunorubicin HCl是一种天然来源的蒽环类抗生素,通过嵌入DNA双链并抑制拓扑异构酶Ⅱ活性,阻断DNA复制与转录,从而诱导肿瘤细胞凋亡。
- GC10405MethotrexateCAS: 59-05-2纯度: >98.00%
甲氨蝶呤(Methotrexate)是一种抗叶酸类抗代谢药,有效抑制二氢叶酸还原酶(DHFR)活性,IC50约为7nM。
- GC10470Nutlin-3a chiralCAS: 675576-98-4纯度: >98.00%
Nutlin-3a 手性是 Nutlin-3 的活性异构体,是鼠类双微体 2 (MDM2) 拮抗剂,IC50 值为 0.09μM。
- GC10480Betulinic acidCAS: 472-15-1纯度: >98.00%
白桦脂酸(Betulinic acid)是一种天然的五环三萜类化合物,是真核细胞拓扑异构酶I的抑制剂,IC 50 值为5μM。
- GC10512Y-27632 dihydrochlorideCAS: 129830-38-2纯度: >98.00%
Y-27632 dihydrochloride 作为一种选择性 Rho 激酶抑制剂,是一种新型支气管扩张剂。
- GC10613Nafamostat Mesylate(FUT-175)CAS: 82956-11-4纯度: >98.00%
Nafamostat Mesylate(FUT-175)是一种合成的丝氨酸蛋白酶抑制剂。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC10350 | TIC10 isomer | 41276-02-2 | >98.00% | |
TIC10 isomer是TIC10/ONC201的类似物。 | ||||
| GC10354 | Daunorubicin HCl | 23541-50-6 | >99.00% / >98.00% | |
Daunorubicin HCl是一种天然来源的蒽环类抗生素,通过嵌入DNA双链并抑制拓扑异构酶Ⅱ活性,阻断DNA复制与转录,从而诱导肿瘤细胞凋亡。 | ||||
| GC10389 | ERB 041 | 524684-52-4 | >98.00% | |
An ERβ agonist | ||||
| GC10397 | PD0325901 | 391210-10-9 | >99.50% | |
PD0325901是一种具口服活性、选择性和非ATP竞争性的丝裂原活化蛋白激酶激酶(MEK)抑制剂,IC 50 值为0.33nM。 | ||||
| GC10405 | Methotrexate | 59-05-2 | >98.00% | |
甲氨蝶呤(Methotrexate)是一种抗叶酸类抗代谢药,有效抑制二氢叶酸还原酶(DHFR)活性,IC50约为7nM。 | ||||
| GC10420 | Apremilast (CC-10004) | 608141-41-9 | >99.50% | |
An orally available PDE4 inhibitor | ||||
| GC10442 | MK-8745 | 885325-71-3 | >99.00% | |
An Aurora A kinase inhibitor | ||||
| GC10467 | Irbesartan | 138402-11-6 | >98.50% | |
Irbesartan是一种血管紧张素II受体(AT1)拮抗剂。 | ||||
| GC10468 | 4EGI-1 | 315706-13-9 | >98.50% | |
An inhibitor of mRNA translation | ||||
| GC10469 | Sulfamethoxypyridazine | 80-35-3 | >99.50% | |
A sulfonamide antibiotic | ||||
| GC10470 | Nutlin-3a chiral | 675576-98-4 | >98.00% | |
Nutlin-3a 手性是 Nutlin-3 的活性异构体,是鼠类双微体 2 (MDM2) 拮抗剂,IC50 值为 0.09μM。 | ||||
| GC10474 | Laquinimod (ABR-215062) | 248281-84-7 | >98.00% | |
An immunomodulator | ||||
| GC10480 | Betulinic acid | 472-15-1 | >98.00% | |
白桦脂酸(Betulinic acid)是一种天然的五环三萜类化合物,是真核细胞拓扑异构酶I的抑制剂,IC 50 值为5μM。 | ||||
| GC10501 | VER-50589 | 747413-08-7 | >99.50% | |
Inhibitor of Hsp90 | ||||
| GC10509 | Cladribine | 4291-63-8 | >99.50% | |
A nucleoside analog and prodrug form of 2-CdATP | ||||
| GC10510 | LDN 57444 | 668467-91-2 | - | |
LDN 57444是一种小分子抑制剂,可阻断UCHL1的去泛素化酶活性(K i =0.40μM;IC 50 =0.88μM),抑制UCHL3的IC 50 值为25μM。 | ||||
| GC10512 | Y-27632 dihydrochloride | 129830-38-2 | >98.00% | |
Y-27632 dihydrochloride 作为一种选择性 Rho 激酶抑制剂,是一种新型支气管扩张剂。 | ||||
| GC10520 | Dextran sulfate sodium salt (M.W 200000) | 9011-18-1 | 不显示 | |
A sulfated polysaccharide | ||||
| GC10567 | TCPOBOP | 76150-91-9 | >98.00% | |
TCPOBOP是一种构成性雄酮受体(CAR)激动剂(EC 50 =0.05μM),能够小鼠诱导肝细胞增殖和肝肿大,但不会造成肝损伤。 | ||||
| GC10585 | Simvastatin (Zocor) | 79902-63-9 | >99.00% / >98.00% | |
An HMG-CoA reductase inhibitor | ||||
| GC10591 | Nelarabine | 121032-29-9 | >99.50% | |
A nucleoside analog used in the treatment of leukemia | ||||
| GC10601 | Ubiquitin Isopeptidase Inhibitor I | 108477-18-5 | >97.00% | |
An activator of caspases | ||||
| GC10610 | Adapalene | 106685-40-9 | >98.00% | |
An RARβ and RARγ agonist | ||||
| GC10613 | Nafamostat Mesylate(FUT-175) | 82956-11-4 | >98.00% | |
Nafamostat Mesylate(FUT-175)是一种合成的丝氨酸蛋白酶抑制剂。 | ||||
